Abbott Laboratories
100 Abbott Park Road
Abbott Park
Illinois
United States
About Abbott Laboratories
1466 articles about Abbott Laboratories
-
Abbott Introduces NeuroSphere™ Virtual Clinic, First-of-its-Kind Remote Neuromodulation Patient-Care Technology in the U.S.
3/8/2021
Abbott (NYSE: ABT) today announced the U.S. launch of NeuroSphere™ Virtual Clinic, a first-of-its-kind technology that allows patients to communicate with physicians, ensure proper settings and functionality, and receive new treatment settings remotely as needed
-
Abbott Receives FDA EUA for Laboratory PCR Assay That Detects and Differentiates SARS-CoV-2, Flu A, Flu B and RSV in One Test - and FDA EUA for Asymptomatic Usage of Alinity m COVID-19 Test
3/5/2021
Abbott (NYSE: ABT) today announced U.S. Food and Drug Administration (FDA) Emergency Use Authorization (EUA) for the company's Alinity™ m Resp-4-Plex molecular assay to detect and differentiate SARS-CoV-2, influenza A, influenza B and respiratory syncytial virus (RSV) in one test.
-
Abbott Researchers Find Rare Group of People With Controlled HIV Who Could Be a Key To Unlocking Cure
3/2/2021
Abbott (NYSE: ABT) announced today that a team of scientists has found an unusually high number of people in the Democratic Republic of Congo (DRC) who test positive for HIV antibodies, but have low to non-detectable viral load counts – without the use of antiretroviral treatment.
-
Abbott Declares 389th Consecutive Quarterly Dividend
2/19/2021
The board of directors of Abbott (NYSE: ABT) today declared a quarterly common dividend of 45 cents per share.
-
Abbott's Panbio Rapid Antigen Test Receives CE Mark for Asymptomatic Screening and Self-Administered Sample Collection with Nasal Swab
1/26/2021
Abbott (NYSE: ABT) announced today it has received CE Mark for two new uses of its Panbio™ COVID-19 Ag Rapid Test Device for the detection of the SARS-CoV-2 virus: asymptomatic testing and self-swabbing.
-
Abbott Receives Expanded Medicare Reimbursement for First-Of-Its-Kind MitraClip™ Device
1/20/2021
Abbott (NYSE: ABT) today announced that the U.S. Centers for Medicare & Medicaid Services (CMS) revised its National Coverage Determination (NCD) to expand coverage for transcatheter edge-to-edge repair (TEER), also referred to as transcatheter mitral valve repair (TMVr), to include patients with secondary (or functional) mitral regurgitation (MR) resulting from heart failure.
-
Abbott Sues Former VP Over Trade Secrets, Similar Cases Expected to Follow in “New Normal”
11/5/2020
Abbott is suing their former VP Jerome Clavel over allegations of trade secret theft with intent to share with his new employer, rival diagnostics company Bio-Rad. -
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for September 30, 2020.
-
One month after the government inked a $750 million contract with Abbott for its new, point-of-care COVID-19 test, President Trump said they will be soon be distributed across the country to double the number of tests being performed in the United States.
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for September 21, 2020.
-
One day after Abbott secured Emergency Use Authorization for its $5 coronavirus test, the White House awarded the company a $750 million contract to deliver 150 million Abbott BinaxNOW COVID-19 Ag Card Point of Care (POC) SARS-CoV-2 diagnostic tests.
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for July 17, 2020.
-
Abbott Agrees to Global Transcatheter Litigation Settlement with Edwards Lifesciences
7/13/2020
Abbott (NYSE: ABT) announced today it has reached an agreement with Edwards Lifesciences Corporation to settle all outstanding patent disputes between the companies in cases related to transcatheter mitral and tricuspid repair products.
-
New Late-Breaking Data Highlight Impact of Abbott's Minimally Invasive Structural Heart Therapies
6/25/2020
Abbott (NYSE: ABT) today announced late-breaking data on a number of its life-changing products to treat people with structural heart diseases.
-
Abbott released a positive interim analysis of an ongoing clinical study assessing the accuracy of its ID NOW COVID-19 rapid that showed the test that can provide results within 15 minutes has a high degree of specificity and sensitivity.
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 22, 2020.
-
Following a study that raises concerns about the accuracy of Abbott’s rapid COVID-19 test for detecting the virus, the U.S. Food and Drug Administration (FDA) announced it will investigate the claims found in a New York University-related study as the company updates its guidance on the ID NOW test.
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 15, 2020.
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 14, 2020.
-
Researchers at a New York hospital compared Abbott’s 15-minute Abbott ID NOW test to another COVID-19 diagnostics device and found that the Abbott system missed 48% of positive cases the other device detected.